KZIA Stock Price History and Quote Analysis Insights for Investors
Kazia Therapeutics Limited
Stock Price Today
Kazia Therapeutics Limited (KZIA) stock declined over -6.51%, trading at $4.53 on NASDAQ, down from the previous close of $4.84. The stock opened at $4.94, fluctuating between $4.53 and $5.08 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Company Information
| Employees | 9 |
| Beta | 2.08 |
| Sales or Revenue | $2.31M |
| 5Y Sales Change% | -0.989% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Kazia Therapeutics Limited (NASDAQ: KZIA) stock price is $4.53 in the last trading session. During the trading session, KZIA stock reached the peak price of $5.08 while $4.53 was the lowest point it dropped to. The percentage change in KZIA stock occurred in the recent session was -6.51% while the dollar amount for the price change in KZIA stock was -$0.32.
The NASDAQ listed KZIA is part of Biotechnology industry that operates in the broader Healthcare sector. Kazia Therapeutics Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. John E. Friend II, M.D.
Chief Executive Officer
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA,
Chief Executive Officer, MD & Executive Director
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Chief Executive Officer, MD & Executive Director
Ms. Karen R. Krumeich
Chief Financial Officer
Ms. Anna Sandham
Company Sec.
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (
Chief Executive Officer, MD & Executive Director
Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD
Company Sec.
KZIA's closing price is 138.16% higher than its 52-week low of $1.90 where as its distance from 52-week high of $15.80 is -71.36%.
Number of KZIA employees currently stands at 9.
Official Website of KZIA is: https://www.kaziatherapeutics.com
KZIA could be contacted at phone 130 078 7272 and can also be accessed through its website. KZIA operates from Three International Towers, Sydney, NSW 2000, Australia.
KZIA stock volume for the day was 47.01K shares. The average number of KZIA shares traded daily for last 3 months was 143.79K.
The market value of KZIA currently stands at $15.06M with its latest stock price at $4.53 and 3.33M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com